Pfizer Inc. and BioNTech SE announced positive topline results from an ongoing phase 3 trial cohort evaluating their LP.8.1-adapted monovalent Comirnaty (COVID-19 Vaccine, mRNA) 2025–2026 Formula. The study focused on adults aged 65+ and adults 18–64 with at least one risk factor for severe COVID-19.
Key Findings from the Trial
- Robust immune response:
- 14 days post-vaccination, neutralizing antibody titers against LP.8.1 increased >4-fold compared to pre-vaccination levels in both age groups. - Study size: 100 participants:
- 50 aged 65+
- 50 aged 18–64 with risk factors. - Prior vaccination:
- All had received the KP.2-adapted vaccine at least six months earlier.
- None had received other COVID-19 vaccines or had COVID-19 infection since then. - Safety profile:
- Consistent with previous studies.
- No new safety concerns reported.
Why It Matters
- Reinforces pre-clinical findings that supported FDA approval of the LP.8.1-adapted vaccine.
- Shows strong immune responses against multiple circulating sublineages of SARS-CoV-2.
- Provides early guidance for prescribers ahead of the 2025–2026 vaccination period.
- Complements, but does not replace, FDA post-marketing study commitments.
Pfizer-BioNTech COVID-19 Vaccine: Global Impact
- 5 billion doses distributed worldwide to date.
- Continues to show favourable safety and efficacy supported by:
- Clinical and preclinical data.
- Real-world evidence.
- Pharmacovigilance monitoring.
- Robust manufacturing data. - Based on BioNTech’s proprietary mRNA technology.
- BioNTech holds marketing authorizations for Comirnaty and its adapted vaccines in:
- United States
- European Union
- United Kingdom
- Other global markets
